One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Amryt Pharma plc logo
Amryt Pharma plc AMYT
report update icon

Quarterly report 2021-Q4
added 05-23-2026

Amryt Pharma plc Financial Statements 2021-2011 | AMYT

Annual Financial Statements Amryt Pharma plc

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.55 B 2.25 B - - - - - - - - -

Shares

236 M 159 M 75.9 M 45.8 M - - - - - - -

Historical Prices

10.8 14.2 - - - - - - - - -

Net Income

1 M -105 M -63 M -30.5 M -31.4 M -8.21 M -39.7 M -2.56 M -2.12 M -826 K -3.06 M

Revenue

223 M 183 M 58.1 M 17.1 M 15.3 M 1.42 M - - - - -

Cost of Revenue

106 M 119 M 38.7 M 6.27 M - - - - - - -

Gross Profit

116 M 63.6 M 19.4 M 10.8 M 8.88 M 805 K - - - - -

Operating Income

-38.6 M -46.5 M -50.5 M -18 M - - - - - - -

EBITDA

-38.6 M -46.5 M -50.5 M -18 M -16.7 M -5.95 M 33.3 M -2.93 M -202 K -275 K -281 K

Operating Expenses

- 109 M 52.2 M 27.9 M 25.9 M 6.95 M - - - - -

General and Administrative Expenses

92 M 76.7 M 35.5 M 17.3 M 13.3 M 4.49 M 3.2 M 2.47 M 1.47 M 275 K 281 K

All numbers in USD currency

Quarterly Income Statement Amryt Pharma plc

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - - 236 M - - - 159 M - - - 75.9 M - - - 45.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- - - - 1 M - - - -105 M - - - -63 M - - - -30.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - 223 M - - - 183 M - - - 58.1 M - - - 17.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - 106 M - - - 119 M - - - 38.7 M - - - 6.27 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - 116 M - - - 63.6 M - - - 19.4 M - - - 10.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - -38.6 M - - - -46.5 M - - - -50.5 M - - - -18 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - -38.6 M - - - -46.5 M - - - -50.5 M - - - -18 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - - 92 M - - - 76.7 M - - - 35.5 M - - - 17.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Amryt Pharma plc AMYT
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Amryt Pharma plc plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Denali Therapeutics Denali Therapeutics
DNLI
$ 18.43 1.29 % $ 3.18 B usaUSA
Pfizer Pfizer
PFE
$ 27.4 -0.62 % $ 156 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 10.56 -6.26 % $ 4.38 B irlandaIrlanda
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 11.08 -0.81 % $ 100 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 1.63 -4.68 % $ 145 M usaUSA
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
$ 93.83 0.32 % $ 6.96 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 27.54 -4.24 % $ 1.6 B usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
$ 68.45 1.08 % $ 29.4 B usaUSA
Equillium Equillium
EQ
$ 1.06 -5.36 % $ 60.7 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.32 -5.04 % $ 75.1 M usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 2.42 -1.17 % $ 128 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 17.1 -2.79 % $ 2.88 B usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 1.6 -8.86 % $ 13.8 M usaUSA
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 112.31 -3.84 % $ 7.3 B usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
- - $ 1.77 B usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.29 -2.28 % $ 164 M schweizSchweiz
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 32.58 -1.21 % $ 1.87 B usaUSA
Ardelyx Ardelyx
ARDX
$ 2.99 -2.25 % $ 721 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 0.39 -8.41 % $ 100 M usaUSA
Alector Alector
ALEC
$ 2.34 1.52 % $ 241 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.06 3.43 % $ 56.9 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 21.12 -1.26 % $ 6.62 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.03 -1.11 % $ 772 M canadaCanada
Agenus Agenus
AGEN
$ 5.97 -2.85 % $ 178 M usaUSA
PolyPid Ltd. PolyPid Ltd.
PYPD
$ 6.1 -6.87 % $ 99.7 M israelIsrael
AbCellera Biologics AbCellera Biologics
ABCL
$ 9.63 -8.02 % $ 2.88 B canadaCanada
Artelo Biosciences Artelo Biosciences
ARTL
$ 1.35 -6.9 % $ 255 K usaUSA
Immatics N.V. Immatics N.V.
IMTX
$ 5.76 -3.19 % $ 705 M germanyGermany
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 0.4 -2.61 % $ 126 K usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 1.22 -2.4 % $ 12.1 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.44 -1.86 % $ 422 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 27.46 -2.1 % $ 4.17 B usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 0.83 -8.27 % $ 2.16 M usaUSA
Biofrontera AG Biofrontera AG
BFRA
- -8.24 % $ 105 M germanyGermany
SIGA Technologies SIGA Technologies
SIGA
$ 2.4 -9.06 % $ 172 M usaUSA
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
- -6.97 % $ 657 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 7.56 0.4 % $ 351 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 28.3 0.68 % $ 1.32 B usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
- 1.68 % $ 4.65 B chinaChina
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 55.64 2.88 % $ 155 M israelIsrael
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
$ 8.71 -4.16 % $ 755 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 3.47 -6.48 % $ 371 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
$ 0.59 -4.42 % $ 36.2 M usaUSA
Jaguar Health Jaguar Health
JAGX
$ 0.24 -27.06 % $ 560 K usaUSA
Arvinas Arvinas
ARVN
$ 6.41 -4.9 % $ 454 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 1.86 -2.37 % $ 355 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 20.87 -0.36 % $ 2.06 B usaUSA
Inhibrx Inhibrx
INBX
$ 68.81 -7.43 % $ 3.24 B usaUSA
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 48.09 -4.54 % $ 5.52 B usaUSA